Compare Ascendis Pharma A/S (ASND) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs IQIYI Inc - ADR — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while IQIYI Inc - ADR trades at $1.11 (market cap $1.09B). The key difference: Ascendis Pharma A/S is far larger — about 16.3× IQIYI Inc - ADR's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| ASND | IQ | |
|---|---|---|
Market Cap | $17.74B | $1.09B |
Sector | Health | Media |
52-Week High | $277.18 | $2.79 |
52-Week Low | $163.32 | $0.96 |
Enterprise Value | $18.11B | $2.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IQ trades at $1.13, down 0.88% on the day, with technical indicators neutral and mixed earnings history. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, though valuation ratios like P/S of 0.28 and P/B of 0.57 suggest potential undervaluation. Recent news highlights AI initiatives and leadership changes, while cash flow trends show volatility with a net inflow of $787.41M in 2025.
The outlook is cautious; analyst consensus is split with 50% buy ratings but profitability concerns persist. Risks include revenue declines, competitive pressures in streaming, and debt levels. Upside potential exists if AI-driven content strategies revive growth, but near-term volatility is likely amid earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
